iPSC Platform for RNA Therapeutics Poster

RNA-based drugs, including antisense oligonucleotides (ASOs), hold enormous promise, but evaluating their safety and efficacy early in the pipeline is a persistent challenge. 

This poster showcases how Ncardia has developed a scalable iPSC-based platform to provide predictive data for ASO drug discovery, combining disease-relevant human cell models with advanced assay systems. Download a copy now for a look at:

• How Ncardia established optimized assay conditions for ASO toxicity testing
• Validation of assay linearity, amplification efficiency, feasibility of multiplexing, and reproducibility in high-throughput formats 
• Data including functional readouts and comparative efficacy testing of multiple ASO candidates at different concentrations